Clinical trial

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Merck KGaA, Darmstadt, GermanyCompletedStarted Jan 1, 2012545 enrolledUnited KingdomNCT01601119

Abstract

The objective is to establish the impact of current disease modifying therapies (DMTs) and associated support services on Patient Reported Experience Measures and Patient Reported Outcomes in relation to the treatment and management of Relapsing Multiple Sclerosis in the United Kingdom (UK).

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

DMT

Keywords

Multiple SclerosisPatient reported outcomePatient reported experienceRelapsing Multiple Sclerosis

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress.

Viña SM

Europe PMC2025

ArticleAyahuasca

Analysis of 28 hair samples from users of the hallucinogenic beverage ayahuasca.

Liu M, Yang H, Hu J +6

Europe PMC2021

ArticleAyahuasca

Validation of an analytical method for the determination of the main ayahuasca active compounds and application to real ayahuasca samples from Brazil.

Souza RCZ, Zandonadi FS, Freitas DP +2

Europe PMC2019